AOD-9604

AOD-9604 is a synthetic peptide derived from a modified fragment of human growth hormone (HGH). It is widely studied for its role in fat metabolism and potential applications in metabolic research.

AOD-9604: Research Overview

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 176–191 of the C-terminus of human growth hormone (hGH). Developed originally as a research compound to isolate the lipolytic properties of hGH, AOD-9604 retains the fat-metabolizing domain while lacking the receptor-binding region responsible for anabolic growth and insulin-sensitizing effects. Its molecular weight is approximately 1,817 Da and it contains a disulfide bond structurally analogous to that found in native hGH.

Preclinical research has centered on three primary areas:

• Lipolysis Stimulation: AOD-9604 has been shown in rodent models to stimulate lipolysis via beta-adrenergic receptor pathways, particularly in visceral adipose tissue, without systemic growth-hormone-like signaling. (Ng et al., 2000)
• Lipogenesis Inhibition: Studies in obese (ob/ob) and Zucker rat models demonstrated reduced fat mass through inhibition of fatty acid synthesis pathways.
• Beta-3 Adrenergic Receptor Modulation: AOD-9604 appears to modulate beta-3 AR expression in adipose tissue, a receptor subtype critical for regulating metabolic rate and thermogenesis in brown adipose tissue.

Researchers studying metabolic peptides frequently compare AOD-9604 with MOTS-c (mitochondrial-derived metabolic regulator) and GLP-1(Sema) (incretin-axis GLP-1 receptor agonist) for their distinct but potentially complementary mechanisms in fat metabolism and energy homeostasis research. For multi-peptide research protocol design, see our Stacking Peptides Research Guide.

Research Context: AOD-9604 in the Metabolic Peptide Landscape

The metabolic research peptide category includes compounds acting at distinct nodes of energy regulation. AOD-9604 occupies a specialized niche as an hGH fragment with selective lipolytic activity:

• AOD-9604 — hGH C-terminal fragment; selective lipolysis via beta-3 AR; no anabolic/IGF-1 pathway activation
• MOTS-c — Mitochondrial peptide; AMP kinase activation, insulin sensitivity, metabolic flexibility
• GLP-1(Sema) — GLP-1 receptor agonist; incretin axis modulation, appetite signaling, beta-cell research
• GLP-2(Tirz) — Dual GIP/GLP-1 agonist; multi-incretin research platform
• NAD+ — Coenzyme; mitochondrial bioenergetics, sirtuin pathway, metabolic aging research

Each mechanism is distinct, providing researchers with complementary tools for investigating adipose biology, energy expenditure, and metabolic dysfunction.

Related Research Resources

• What Are Peptides: The Complete 2026 Research Guide
• Peptide Stacking Research Guide: Synergistic Combinations
• How to Reconstitute Peptides Safely for R&D
• Quality Control in Peptide Research: Interpreting Purity
• Peptide Safety 101: Finding the Safest Place to Buy Peptides

Key Properties

• Fat Metabolism Studies: Investigated for its potential to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat formation).
• Receptor Activation Research: Explored for its interaction with beta-3 adrenergic receptors in adipose tissue.
• Energy Conversion: Studied for its ability to enhance cellular energy production in laboratory settings.

Applications in Research

AOD-9604 is the subject of extensive research focusing on:

• Mechanisms of lipolysis and fat metabolism.
• Interaction with adrenergic receptors and its role in energy regulation.
• Cellular pathways related to adipose tissue and metabolic studies.

These investigations are conducted in laboratory settings to expand scientific understanding.

Storage and Handling Instructions

• Store lyophilized AOD-9604 in a sealed container at -4°F (-20°C) or lower.
• Protect from light, moisture, and excessive heat.
• Discard unused or reconstituted solutions immediately after use following research protocols.

Safety Information

This product is intended for research purposes. You must:

• Follow institutional and regulatory safety guidelines during handling and disposal.
• Use appropriate protective equipment.

Frequently Asked Questions

What is AOD-9604?
AOD-9604 is a synthetic peptide derived from human growth hormone, studied for its role in fat metabolism and its interaction with adipose tissue.

How should AOD-9604 be stored?
Store at -4°F (-20°C) or lower in a light-protected environment. Once reconstituted, keep at 36°F to 46°F (2°C to 8°C) and use promptly.

What are the primary research focuses of AOD-9604?
The research investigates its impact on lipolysis, fat metabolism, and its interaction with beta-3 adrenergic receptors in adipose tissue.

Frequently Asked Questions

What is AOD-9604 and how is it classified in research?

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 176-191 of the C-terminus of human growth hormone (hGH). In preclinical research models, it has been investigated for its selective lipolytic properties without the growth-promoting or insulin-sensitizing effects associated with full-length hGH. Studies are conducted exclusively in controlled laboratory environments.

What is the molecular structure of AOD-9604?

AOD-9604 consists of 16 amino acids derived from the C-terminal region of hGH and includes a disulfide bond that mimics the native hGH structure. Its molecular weight is approximately 1,817 Da. The peptide retains the lipolytic domain of hGH while lacking the receptor-binding region responsible for anabolic growth effects.

How should AOD-9604 be stored for laboratory research?

Lyophilized AOD-9604 should be stored at -20 degrees C or lower, protected from light and moisture. Once reconstituted with sterile or bacteriostatic water, the solution should be used promptly per the research protocol. Repeated freeze-thaw cycles should be avoided to preserve structural integrity.

What purity standards apply to research-grade AOD-9604?

Research-grade AOD-9604 should demonstrate greater than or equal to 98% purity as verified by HPLC analysis. In-house purity testing ensures batch consistency.

What metabolic pathways has AOD-9604 been studied in preclinical models?

Published preclinical studies have investigated AOD-9604 primarily in the context of adipose tissue lipolysis, fat oxidation, and beta-adrenergic receptor expression in obese rodent models including ob/ob and Zucker rat systems. These investigations are conducted exclusively in controlled laboratory and animal model settings.

How is AOD-9604 typically prepared for use in preclinical studies?

In laboratory settings, AOD-9604 is reconstituted with sterile-filtered bacteriostatic water. Researchers use calibrated micro-syringes for precise dosing in animal model studies. All procedures must follow institutional biosafety protocols and applicable regulatory guidelines for peptide research.

References

1. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.” Horm Res. 2000;53(6):274-8.. PubMed
2. Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. “Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.” Int J Obes Relat Metab Disord. 2001;25(10):1442-9.. PubMed
3. Heffernan M, et al. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.” Endocrinology. 2001;142(12):5051-7.. PubMed
4. Halford JC. “Obesity drugs in clinical development.” Curr Opin Investig Drugs. 2006;7(4):312-8.. PubMed